MarketBeat
19 May 2026, 14:14 UTC · 20w ago
Impact · against what's priced in
The article provides several catalyst-driven updates, most notably the first-in-class FDA approval for Arvinas and a significant revenue collapse for BioNTech. These events, along with an upgrade for Landstar and guidance raises for AudioCodes, present material shifts in valuation drivers across the reported names.
No priced-in read yet
What the story claims
6 claims · scored −1 bearish … +1 bullish
BioNTech's second-quarter 2026 revenue fell to €106 million from €261 million a year earlier due to lower U.S. demand for its COVID-19 vaccine.
More negative than 99% of claims this week
Arvinas received FDA approval for VEPPANU, the first approved PROTAC degrader.
So whatFirst-in-class FDA approval is a major catalyst for biotech valuation and future commercial revenue.
Continue reading
5 related stories
The company achieved a major milestone with the FDA approval of VEPPANU, the first approved PROTAC degrader.
Read from the article alone
No priced-in read yet
Wolfe Research upgraded the stock to 'outperform' with a $214.00 price target.
Read from the article alone
No priced-in read yet
Record performance in the Renewables segment and improved fertilizer operations drove sharply higher second-quarter earnings.
Read from the article alone
Scored by the NIS engine · methodology.
Top 2 movers · tap to explore
More positive than 98% of claims this week
Wolfe Research upgraded Landstar System to 'outperform' with a $214.00 price objective.
More positive than 87% of claims this week
AudioCodes raised its full-year revenue outlook following a 3.1% increase in second-quarter revenue.
So whatRaising forward guidance signals management confidence and typically supports a higher stock valuation.
More positive than 79% of claims this week
Which stocks this story touches
More positive than 87% of ticker scores this week
Reported sharply higher second-quarter earnings driven by record performance in its Renewables segment.
More positive than 87% of ticker scores this week
Wolfe Research upgraded the company from 'peer perform' to 'outperform' with a $214 price target.
More positive than 81% of ticker scores this week
Achieved strategic milestones including FDA approval of its first PROTAC degrader.
More negative than 79% of ticker scores this week
Reported a significant drop in second-quarter revenue due to lower demand for its COVID-19 vaccine.
More positive than 75% of ticker scores this week
Reported revenue growth and raised its full-year revenue outlook.
More positive than 55% of ticker scores this week
Reported slight revenue growth and reaffirmed full-year outlook.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
24/7 Wall Street
1h ago
−5.2%
Price is moving against the score
$169.81 vs $179.11 close before publication (May 18) · not market-adjusted
LSTR chart →−16.4%
Price is moving against the score
$7.34 vs $8.78 close before publication (May 18) · not market-adjusted
ARVN chart →−5.2%
Price is moving against the score
$67.19 vs $70.85 close before publication (May 18) · not market-adjusted
ANDE chart →
